Results 31 to 40 of about 29,283 (148)

Clinical and educational impact of pharmacogenomics testing: a case series from the INGENIOUS trial [PDF]

, 2017
Pharmacogenomic testing has become increasingly widespread. However, there remains a need to bridge the gap between test results and providers lacking the expertise required to interpret these results.
Desta, Zeruesenay, Eadon, Michael T., Gufford, Brandon T., Pierson, Rebecca C.   +3 more
core   +1 more source

Expert Consensus on the Clinical Application of PI3K/AKT/mTOR Inhibitors in the Treatment of Breast Cancer (2025 Edition)

Cancer Innovation, Volume 4, Issue 3, June 2025.
ABSTRACT Background The phosphoinositide 3‐kinase (PI3K)/protein kinase B (PKB or AKT)/mammalian target of rapamycin (mTOR) signaling pathway (PAM pathway) plays a critical role in breast cancer pathogenesis and progression, and is closely linked with resistance to endocrine therapy in advanced breast cancer.
The Breast Cancer Expert Committee of the National Quality Control Center for Cancer, The Expert Committee on Cancer Prevention and Treatment of the Health China Research Center, The Society of Clinical Research on Oncology Medications of the China Anti‐Cancer Association, The Society of Onco‐Pathology of the China Anti‐Cancer Association   +3 more
wiley   +1 more source

Drug-drug interactions : from knowledge base to clinical impact [PDF]

, 2014
Drug usage has increased steadily, and the more drugs used, the higher the risk for adverse effects or loss of effect due to drug-drug interactions. For drug prescribers it is difficult to know what drugs a patient is taking and whether they interact.
Andersson, Marine
core   +1 more source

Concomitant Use of Etrasimod With Opioids or Antidepressants in Patients With Ulcerative Colitis—A Safety Analysis

United European Gastroenterology Journal, Volume 13, Issue 5, Page 719-727, June 2025.
ABSTRACT Background Etrasimod is an oral, once‐daily (q.d.), selective sphingosine 1‐phosphate (S1P)1,4,5 receptor modulator for the treatment of moderately to severely active ulcerative colitis (UC). Unlike the S1P receptor modulator ozanimod, etrasimod does not have a molecular structure to inhibit monoamine oxidase (MAO).
Anita Afzali, Miguel Regueiro, Andres J. Yarur, Yamile Zabana, Siew C. Ng, Sujatha Menon, Aoibhinn McDonnell, Krisztina Lazin, Michael Keating, Abhishek Bhattacharjee, Diogo Branquinho, Eustratios Bananis, Laurent Peyrin‐Biroulet   +12 more
wiley   +1 more source

Multi-site investigation of strategies for the clinical implementation of CYP2D6 genotyping to guide drug prescribing [PDF]

, 2019
PURPOSE: A number of institutions have clinically implemented CYP2D6 genotyping to guide drug prescribing. We compared implementation strategies of early adopters of CYP2D6 testing, barriers faced by both early adopters and institutions in the process
Beitelshees, Amber L., Bell, Gillian C., Bishop, Jeffrey R., Blake, Kathryn, Cavallari, Larisa H., Crona, Daniel J., Dressler, Lynn, Duong, Benjamin Q., Empey, Philip E., Gregg, Ryan A., Hicks, J. Kevin, Hines, Lindsay J., Johnson, Julie A., Lee, James C., Limdi, Nita A., Obeng, Aniwaa Owusu, Peterson, Josh F., Pratt, Victoria M., Prows, Cynthia A., Ramsey, Laura B., Scott, Stuart A., Shelton, Richard C., Skaar, Todd C., Smith, D. Max, Tuteja, Sony, Van Driest, Sara L., Weitzel, Kristin Wiisanen   +26 more
core   +1 more source

In Vitro Investigations into the Potential Drug Interactions of Pseudoginsenoside DQ Mediated by Cytochrome P450 and Human Drug Transporters

Molecules
Pseudoginsenoside DQ (PDQ), an ocotillol-type ginsenoside, is synthesized with protopanaxadiol through oxidative cyclization. PDQ exhibits good anti-arrhythmia activity.
Zhuo Li, Cuizhu Wang, Jinping Liu, Pingya Li, Hao Feng   +4 more
doaj   +1 more source

Economic Impact of the Application of a Precision Medicine Model (5SPM) on Psychotic Patients

Pharmacogenomics and Personalized Medicine, 2021
Lorena Carrascal-Laso,1 Manuel Ángel Franco-Martín,1 Elena Marcos-Vadillo,2 Ignacio Ramos-Gallego,3 Belén García-Berrocal,2 Eduardo Mayor-Toranzo,1 Santiago Sánchez-Iglesias,4 Carolina Lorenzo,4 Alfonso Sevillano-Jiménez,1 Almudena Sánchez-Martín,5 María
Carrascal-Laso L, Franco-Martín M, Marcos-Vadillo E, Ramos-Gallego I, García-Berrocal B, Mayor-Toranzo E, Sánchez-Iglesias S, Lorenzo C, Sevillano-Jiménez A, Sánchez-Martín A, García-Salgado MJ, Isidoro-García M   +11 more
doaj  

hESCs‐derived Organoids Achieve Liver Zonation Features through LSEC Modulation

Advanced Science, Volume 12, Issue 20, May 29, 2025.
This article addresses the absence of zonation features in current organoid models by co‐culturing human embryonic stem cell‐derived hepatocytes with liver sinusoidal endothelial cells exhibiting distinct zonal characteristics. It demonstrates that differential WNT2 signaling from endothelial cells modulates hepatocyte zonation and metabolic functions,
Yuying Zhang, Chenyan Huang, Lei Sun, Lyu Zhou, Yudi Niu, Kaini Liang, Bingjie Wu, Peng Zhao, Zhiqiang Liu, Xiaolin Zhou, Peng Zhang, Jianchen Wu, Jie Na, Yanan Du   +13 more
wiley   +1 more source

The role of biotransformation processes in mediating interactions between psychotropic drugs and natural products [PDF]

, 2020
Many patients are not aware that natural products such as fruit juices or plant infusions can cause significant interactions with several drugs, some of which can be dangerous, especially when the medical treatment is for neurological or psychiatric ...
Bacinschi, Nicolae, Chianu, Marin, Mihalachi-Anghel, Maria, Podgurschi, Lilia, Pogonea, Ina, Socea, Bogdan, Ștefănescu, Emil   +6 more
core   +2 more sources

Polymorphic drug metabolising enzymes:Assessment of activities by phenotyping and genotyping in clinical pharmacology [PDF]

, 2001
Drug effects (pharmacodynamics) are determined by drug concentration at target site and the affinity of the drug for a target. Pharmacogenetics describes inherited differences in drug metabolising enzyme activities and differences in drug transporters ...
Tamminga, Willem Jan
core   +2 more sources